Kestra Medical Technologies, Ltd. (NASDAQ:KMTS) Given Consensus Recommendation of “Moderate Buy” by Analysts

Kestra Medical Technologies, Ltd. (NASDAQ:KMTS) has been assigned an average rating of “Moderate Buy” from the eight analysts that are presently covering the stock, Marketbeat reports. One investment analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and six have given a buy recommendation to the company. The average 12 month price objective among analysts that have updated their coverage on the stock in the last year is $29.00.

KMTS has been the topic of several research analyst reports. Weiss Ratings restated a “sell (d-)” rating on shares of Kestra Medical Technologies in a research note on Wednesday, December 24th. Piper Sandler lifted their target price on shares of Kestra Medical Technologies from $27.00 to $30.00 and gave the company an “overweight” rating in a research note on Friday, December 12th. The Goldman Sachs Group set a $24.00 price objective on shares of Kestra Medical Technologies in a report on Friday, January 16th. Stifel Nicolaus set a $30.00 price target on shares of Kestra Medical Technologies in a research note on Friday, December 12th. Finally, Wells Fargo & Company boosted their target price on shares of Kestra Medical Technologies from $27.00 to $28.00 and gave the stock an “overweight” rating in a report on Friday, December 12th.

Kestra Medical Technologies Trading Down 2.0%

Shares of NASDAQ KMTS opened at $25.55 on Thursday. Kestra Medical Technologies has a 52-week low of $13.25 and a 52-week high of $30.00. The firm’s 50 day moving average price is $25.62 and its 200-day moving average price is $23.59. The company has a debt-to-equity ratio of 0.26, a quick ratio of 5.47 and a current ratio of 5.47. The company has a market cap of $1.49 billion and a PE ratio of -8.06.

Insider Transactions at Kestra Medical Technologies

In other news, insider Traci S. Umberger sold 10,500 shares of the company’s stock in a transaction that occurred on Monday, December 29th. The stock was sold at an average price of $26.69, for a total transaction of $280,245.00. Following the transaction, the insider owned 136,633 shares of the company’s stock, valued at approximately $3,646,734.77. This represents a 7.14% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, insider Brian Daniel Webster sold 15,000 shares of the firm’s stock in a transaction that occurred on Thursday, January 15th. The stock was sold at an average price of $22.80, for a total value of $342,000.00. Following the sale, the insider directly owned 394,786 shares of the company’s stock, valued at $9,001,120.80. This represents a 3.66% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 40,500 shares of company stock worth $1,021,095 over the last three months. 3.60% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Kestra Medical Technologies

Hedge funds and other institutional investors have recently modified their holdings of the business. Jennison Associates LLC lifted its position in shares of Kestra Medical Technologies by 79.0% during the second quarter. Jennison Associates LLC now owns 134,272 shares of the company’s stock valued at $2,226,000 after buying an additional 59,272 shares during the last quarter. Franklin Resources Inc. grew its position in Kestra Medical Technologies by 32.4% during the 2nd quarter. Franklin Resources Inc. now owns 441,398 shares of the company’s stock worth $7,318,000 after purchasing an additional 108,103 shares during the last quarter. Brown Advisory Inc. raised its stake in Kestra Medical Technologies by 5.4% in the 2nd quarter. Brown Advisory Inc. now owns 580,025 shares of the company’s stock worth $9,617,000 after acquiring an additional 29,607 shares during the last quarter. Eventide Asset Management LLC increased its holdings in shares of Kestra Medical Technologies by 285.7% in the second quarter. Eventide Asset Management LLC now owns 1,060,557 shares of the company’s stock valued at $17,584,000 after purchasing an additional 785,557 shares during the period. Finally, Police & Firemen s Retirement System of New Jersey acquired a new stake in shares of Kestra Medical Technologies in the second quarter worth $54,000.

About Kestra Medical Technologies

We are a commercial-stage, wearable medical device and digital healthcare company focused on transforming patient outcomes in cardiovascular disease using monitoring and therapeutic intervention technologies that are intuitive, intelligent, and connected. We have developed and are commercializing our Cardiac Recovery System platform, a comprehensive and advanced system that integrates monitoring, therapeutic treatment, digital health, and patient support services into a single, unified solution. The cornerstone of our Cardiac Recovery System platform is the ASSURE WCD, a next generation wearable cardioverter defibrillator (“WCD”) used to protect patients at an elevated risk of sudden cardiac arrest (“SCA”), a major public health problem that accounts for approximately 50% of all cardiovascular deaths in the U.S.